Financial News · Live Terminal

Page 127 of 171

Research Alert: CFRA Maintains Hold Recommendation On Shares Of Alcoa Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our 12-month target by $7 to $75, assuming an EV/EBITDA of 6.5x our 2027 EBITDA estimate, a discount to AA's three-year average forward EV/EBITDA of 6.7x, warranted by the Section 232 tariffs, a headwind for AA's cost basis. We raise our 2026 EPS estimate by $2.97 to $7.78 and our 2027 EPS estimate by $0.57 to $6.12. AA benefits from a favorable aluminum supply-demand backdrop stemming from the Middle East conflict, which has taken approximately 2.5 million metric tons of annual smelting capacity offline and pushed LME aluminum prices above $3,600/ton. AA's strategic advantages include minimal spot electricity exposure (less than 1%) and growing demand for value-added products from customers seeking to replace Middle East supply. However, the alumina segment faces margin pressure from weak API pricing and elevated energy costs. With $1.4 billion in cash and debt reduction underway, AA is well positioned to benefit from sustained tight aluminum markets while navigating alumina headwinds.

$AA

Research18d ago

Research Alert: CFRA Drops Stars Coverage Of Six Flags Entertainment Corp

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We are dropping analytical coverage of FUN, an amusement park operator, due to a shift in investor focus. Our previous recommendation was Hold.

$FUN

Research18d ago

Daiwa Downgrades Abbott Laboratories to Neutral From Outperform, Adjusts PT to $92 From $113

Abbott Laboratories (ABT) has an average rating of overweight and mean price target of $119.08, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ABT

Research18d ago

Rothschild & Co Redburn Downgrades Albemarle to Neutral From Buy, Adjusts PT to $188 From $185

Albemarle (ALB) has an average rating of overweight and mean price target of $199.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ALB

Research18d ago

Jefferies Downgrades Prudential Financial to Hold From Buy, Adjusts Price Target to $98 From $124

Prudential Financial (PRU) has an average rating of hold and mean price target of $100.93, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$PRU

Research18d ago

Research Alert: CFRA Drops Stars Coverage Of Tripadvisor Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We are dropping analytical coverage of TRIP, an online travel agency, due to a shift in investor focus. Our previous recommendation on shares of TRIP was Hold.

$TRIP

Research18d ago

Research Alert: CFRA Keeps Hold Opinion On Adss Of Nio Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our target to USD7.00 from USD6.50, which implies a 2026 P/S of 1.0x (below its five-year mean of 2.7x), on our projected slower two-year revenue CAGR of 29% (vs. its historical five-year CAGR of 40% through 2025). We project NIO's revenue to grow 33%/25% in 2026/2027, assuming the number of car deliveries will increase by 40%/30% in 2026/2027, led by demand for upcoming new models (including the ONVO L80, ES9, and five-seat ES7). We expect non-GAAP net losses to narrow, supported by an improved product mix and enhanced scale efficiencies. Nevertheless, intensifying price competition, policy headwinds, and elevated costs are likely to delay profitability improvement, with breakeven unlikely to materialize before 2028. Improved delivery growth and margin trajectory are encouraging, but insufficient to warrant a more constructive stance until the company demonstrates a clear path to profitability. We revise our non-GAAP LPADS forecast to CNY0.42 (from CNY0.51) for 2026 and set 2027's LPADS at CNY0.09.

$NIO

Research19d ago

Nomura Starts Leela Palaces Hotels & Resorts at Buy with INR510 Price Target

Leela Palaces Hotels & Resorts (NSE:CHALET, BOM:542399) has an average rating of buy and mean price target of 553.81 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$BOM:544408$NSE:THELEELA

Research19d ago

Nomura Starts Chalet Hotels at Neutral with INR860 Price Target

Chalet Hotels (NSE:CHALET, BOM:542399) has an average rating of buy and mean price target of 1,024.05 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$BOM:542399$NSE:CHALET

Research19d ago

Research Alert: Bhp Raises Copper Outlook On Escondida Strength, Cuts Unit Costs Significantly

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BHP delivered solid nine-month operational performance with copper production of 1,460.9kt, down 3% Y/Y, due to lower Escondida grades, while iron ore achieved record production of 196.6Mt, up 2%. Average realized copper prices surged 31% Y/Y to USD5.47/lb, led by AI infrastructure demand and electrification trends, with iron ore averaging USD84.91/wmt, up 2%. Strong operational momentum at key assets including record material mined at Escondida and excellence at WAIO support the investment thesis despite grade headwinds. Management upgraded FY 26 (Jun.) copper guidance to the upper half of the 1,900-2,000kt range, reflecting operational confidence. BHP's disciplined capital management realized USD4.8B through strategic transactions, including the Antamina streaming deal, enabling focus on growth projects. Escondida's unit cost guidance was lowered to USD1.00-1.20/lb, reflecting operational excellence, while the Resolution Copper land exchange milestone advances a major untapped copper resource.

$BHP

Research19d ago

Research Alert: CFRA Drops Stars Coverage Of Tripadvisor Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We are dropping analytical coverage of TRIP, an online travel agency, due to a shift in investor focus. Our previous recommendation on shares of TRIP was Hold.

$TRIP

Research19d ago

Research Alert: CFRA Drops Stars Coverage Of Six Flags Entertainment Corp

$FUN

Research19d ago

Research Alert: CFRA Reiterates Strong Buy View On Shares Of 3m Company

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price at $185 following MMM's Q1 earnings print, valuing shares at 19.4x our 2027 operating EPS outlook of $9.53 (up from $9.26; 2026 EPS view raised to $8.82 from $8.63), near MMM's historical multiple pre-pandemic. Given the company's improving earnings quality and portfolio optimization efforts, we currently see shares as attractively valued. While the macroeconomic environment remains highly dynamic, we do not see this as an exclusive driver of share performance - execution on internal initiatives will be a core determinant of the company's results as its transformation matures. Automation presents a meaningful opportunity in driving the next leg of productivity enhancements, which we see as a tailwind for operating margins as investments bear fruit. On the growth front, we are encouraged by MMM's efforts to lean into data center market expansion, with "Expanded Beam Optics" technology showing early traction among hyperscalers. We reiterate our Strong Buy on shares.

$MMM

Research19d ago

Research Alert: CFRA Reiterates Strong Buy View On Shares Of 3m Company

$MMM

Research19d ago

Research Alert: CFRA Keeps Buy Rating On Shares Of Intuitive Surgical, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $590 from $645, 52.7x our 2027 EPS estimate, below ISRG's five-year average forward P/E of 58x. We raise our 2026 EPS forecast to $10.09 from $9.78 to reflect the Q1 beat and maintain our 2027 EPS estimate at $11.19. We maintain a neutral outlook on the health care equipment sub-industry, as we see positive long-term tailwinds balancing out near-term headwinds. We think that the sub-industry's underperformance relative to the S&P 500 since the beginning of the year accentuated since the onset of the U.S.-Iran conflict in February. This reflects investor caution around near-term operational challenges for Medtech companies, particularly around supply chain, despite the sub-industry's attractive longer-term growth trajectory. We think ISRG shares are trading attractively at current valuations given its robust outlook despite the weakness seen in recent months, which we mainly attribute to the overall negative sentiment for the sub-industry's near-term pressures.

$ISRG

Research19d ago

Research Alert: Eqt: A Strong Q1 Led By Better Pricing

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:EQT kicked off 2026 with a solid earnings beat, reporting adjusted EPS of $2.33 vs. $1.18, beating consensus by $0.24. The pricing environment provided significant tailwinds, with average realized prices of $5.08/Mcfe up 35% and volumes of 618 Bcfe up 8%. Growth drivers are tied to data center demand and LNG exports, with the company targeting Northern Virginia and Southeast markets for incremental data center and industrial demand. EQT guided to unchanged CY26 volume guidance of 2,275-2,375 Bcfe, though plans Q2 production cuts of 10-15 Bcfe due to recent pricing weakness with front-month Henry Hub around $2.75/Mcfe. The company plans CY 26 capex of $2.65B-$2.85B, implying 18% growth at the midpoint. Record quarterly FCF of $1.83B (up 77%) enabled further balance sheet strengthening, with net debt declining to $5.7B as EQT approaches its $5B long-term debt target. Total per-unit operating costs of $1.09/Mcfe came in below management guidance.

$EQT

Research19d ago

Research Alert: Wrb Beats Q1 Eps But Premium Growth Slows Sharply, Raising Valuation Risk

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:WRB posted Q1 2026 operating EPS of $1.30 versus $1.05 a year ago, exceeding our $1.09 estimate and $1.14 consensus forecast. However, net written premium growth continued decelerating to just 1.3% from 9.9% in Q1 2025, raising concerns about WRB's ability to maintain above-peer top-line growth. We applaud WRB's facile underwriting model that allows capital allocation to the healthiest areas, but slowing premium trends could weigh on shares and imperil their premium valuation versus peers. Management expressed cautious optimism, noting margins "will continue to be excellent" while emphasizing effective capital management through 4.5M share repurchases in Q1. WRB's combined ratio improved modestly to 90.7% from 90.9%, with the Insurance segment deteriorating to 92.2% while Reinsurance improved to 78.6%. We note WRB's Q1 operating ROE of 21.2% remains well above the 15%-17% peer average, but challenging market conditions may prove difficult for sustaining premium growth rates.

$WRB

Research19d ago

Research Alert: Sonoco Products Co Q1: Revenue Below Consensus, Margins Down Y/y

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:SON's Q1 2026 results highlight persistent operational challenges, with net sales of $1.676B declining 1.9% Y/Y and missing consensus by $33M, primarily due to the November 2025 ThermoSafe divestiture. Adjusted EPS of $1.20 fell 13.0% from $1.38 in the prior year, though meeting consensus estimates, while GAAP improvements reflected favorable tax adjustments and divestiture impacts rather than underlying operational strength. The transformed portfolio continues facing headwinds despite management's strategic repositioning efforts. The significant adjusted metrics decline contrasts with GAAP improvements, suggesting the operational challenges may persist as the company navigates its post-divestiture structure. We believe the weak adjusted performance underscores concerns about the company's ability to generate sustainable growth from its current portfolio mix, particularly given the revenue shortfall relative to expectations.

$SON

Research19d ago

Research Alert: Ewbc: Q1 Earnings Beat As Revenue Growth Outperforms

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:EWBC posted strong Q1 2026 results with operating EPS of $2.57 vs. $2.08 a year ago, $0.10 above consensus. Q1 revenue of $774M beat consensus by 3% and rose 12% Y/Y and 2% Q/Q. It was another record quarter as the bank reported record levels of loans, deposits, and fee income, while maintaining healthy credit quality. Net interest income outperformed with 2% Q/Q growth while the net interest margin improved 8 bps to 3.49%, driven by a 21-bp decline in deposit costs to 2.84% that more than offset a 9-bp decrease in loan yields. Balance sheet growth remained robust with total loans reaching a record $58B (+2% Q/Q, +7% Y/Y) and deposits hitting $69B (+3% Q/Q, +9% Y/Y). Loan growth was well diversified across commercial and industrial, commercial real estate, and residential mortgage portfolios. Fee income surged 13% Q/Q to record levels, with wealth management fees more than doubling. The bank's funding optimization efforts continued to bear fruit in the competitive environment.

$EWBC

Research19d ago

Research Alert: CFRA Maintains Buy Rating On Shares Of Quest Diagnostics

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month price target at $235. This is based on a forward P/E of 21.9x our 2026 EPS estimate, a premium to DGX's three-year forward average of 16.8x due to our view of strengthening sales and earnings growth, backed by higher health care utilization trends and some regulatory relief due to postponement of lab reimbursement cuts until at least 2027. We think lab testing providers remain a relatively well-positioned area within health care given lower policy risks, supportive testing demand, and attractive earnings growth potential. On a compounded annual basis from 2025-2028, we expect near 8% EPS growth, raising our 2026 EPS to $10.73 from $10.60 and 2027 EPS to $11.50 from $11.42. We also anticipate additional smaller M&A opportunities, along with healthy dividend increases (recent 7.5% boost; shares yield 1.7%) as cash flow generation remains supportive over the near term.

$DGX

Showing 2521-2540 of 3408